| 熊义祥,姜雨,黄勇,等.利伐沙班治疗慢性下肢深静脉血栓的疗效及其对血管内皮功能的影响[J].中国临床保健杂志,2019,22(3):409-411. |
| 利伐沙班治疗慢性下肢深静脉血栓的疗效及其对血管内皮功能的影响 |
| The effects of rivaroxaban in the treatment of chronic lower extremity deep venous thrombosis and on endothelial function |
| 投稿时间：2019-02-15 |
| DOI：10.3969/J.issn.1672-6790.2019.03.032 |
| 中文关键词: 静脉血栓形成 利伐沙班 华法林 内皮,血管 下肢 |
| 英文关键词: Venous thrombosis Rivaroxaban Warfarin Endothelium,vascular Lower extremity 〖FL |
| 基金项目:四川省宜宾市第一批重点科技计划项目(2016SF018) |
|
| 摘要点击次数: 6033 |
| 全文下载次数: 4546 |
| 中文摘要: |
| 目的 探讨利伐沙班治疗慢性下肢深静脉血栓的临床价值。方法 选取68例慢性下肢深静脉血栓形成患者,进行6个月的抗凝治疗,其中以新型抗凝药利伐沙班治疗的为治疗组(34例),以传统抗凝药华法林治疗的为对照组(34例),比较利伐沙班和华法林对慢性静脉血栓的疗效及安全性。结果 治疗组和对照组的有效率分别为97.06%和94.12%,差异无统计学意义(P>0.05)；治疗组的出血率(23.53%)低于对照组(38.24%),差异无统计学意义(P>0.05)；治疗组静脉血栓栓塞症(VTE)的复发率为5.89%显著低于对照组23.53%,差异有统计学意义(P<0.05)；治疗组使用期间无调药和停药,而对照组发生率为32.35和8.82%,差异有统计学意义(P<0.05)；各组内皮功能如血纤溶酶活性、血管性血友病因子、血浆纤溶酶原激活物、组织型纤溶酶原激活物抑制物、血浆纤溶酶原激活物抑制物-1、6-酮前列腺素f1α和血浆内皮素-1较治疗前均明显改善(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论 新型抗凝药利伐沙班对慢性深静脉血栓的疗效显著,能显著降低血栓栓塞复发率,改善内皮功能。 |
| 英文摘要: |
| Objective To investigate the clinical value of rivaroxaban in the treatment of chronic lower extremity deep venous thrombosis.Methods Sixty-eight patients with chronic deep venous thrombosis diagnosed were enrolled and treated with anticoagulant therapy for 6 months.The new anticoagulant rivaroxaban was used as the treatment group (34 cases),the traditional anticoagulant warfarin was used as the control group (34 cases) to explore the efficacy and safety of rivaroxaban and warfarin for chronic venous thrombosis.Results The effective rates of the treatment group and the control group were 97.06% and 94.12%,respectively,and there was no statistically significant difference (P>0.05).The bleeding rate of the treatment group was 23.53% and lower than that of the control group (38.24%),but there was no statistically significant difference (P>0.05).The recurrence rate of VTE in the treatment group was 5.89% and significantly lower than that in the control group (23.53%,P<0.05).There was no adjustment and withdrawal during the treatment group,which was 32.35% and 8.82% in control group.There was statistically significant difference between two groups (P<0.05).The endothelial function of each group such as PLA,vWFAg,tPA,PAI,6-Keto-PG f1α,PLA were significantly improved compared with before treatment (P<0.05),but there was no significant difference between groups (P>0.05).Conclusion The new anticoagulant rivaroxaban has a significant effect on chronic deep venous thrombosis and can significantly reduce the recurrence rate of thromboembolism and improve endothelial function. |
|
查看全文
|
| 关闭 |
|
|
|